BACK
Project/Company Name
M-Cube Scientific Limited
Project Leader
Source of Funding/Programme
TSSSU
Description
Stroke is the second leading cause of death worldwide, with over 12.2 million new cases annually. In the United States, approximately 795,000 people experience a stroke each year. Ischemic strokes account for about 87% of all strokes. Current treatment of ischemic stroke includes use of thrombolytic agent (drug to dissolve the clot) and/or thrombectomy (mechanically remove the clot), which have one or more of the following disadvantages, risk of internal bleeding, require expertise surgeons and cannot reach deep region of brain. MagMint is dedicated to use magnetic microrobots for treating endovascular diseases; our first target is acute ischemic stroke.
Project/Company Name
M-Cube Scientific Limited
Project Leader
Source of Funding/Programme
TSSSU
Description
Stroke is the second leading cause of death worldwide, with over 12.2 million new cases annually. In the United States, approximately 795,000 people experience a stroke each year. Ischemic strokes account for about 87% of all strokes. Current treatment of ischemic stroke includes use of thrombolytic agent (drug to dissolve the clot) and/or thrombectomy (mechanically remove the clot), which have one or more of the following disadvantages, risk of internal bleeding, require expertise surgeons and cannot reach deep region of brain. MagMint is dedicated to use magnetic microrobots for treating endovascular diseases; our first target is acute ischemic stroke.
Starting Year
2025
Business Area
Engineering
Nature
TSSSU Company